ESOXC-ER Efficacy and Safety of an Extended Release (ER) Formulation of Oxcarbazepine (Apydan Extent) in Epileptic Patients

Desitin Arzneimittel GmbH225 enrolled

Overview

The aim of the observational study is to investigate the safety of oxcarbazepine extended release (ER) during long-term therapy in epileptic patients. In addition, quality of life parameters should be documented if assessed.

Study Type

OBSERVATIONAL

Enrollment

225

Conditions

Epilepsy

Eligibility

Sex: ALLMin age: 6 Years

Medical Language ↔ Plain English

Inclusion Criteria: * patients with focal epileptic seizures with or without secondary generalised tonic-clonic seizures * mono- or combination therapy * male and female from the age of 6 Exclusion Criteria: * hypersensitivity to oxcarbazepine MR or one of its excipients

Locations (1)

Dr. Stephan Arnold

Munich, Bavaria, Germany

Outcomes

Primary Outcomes

tolerability and safety

Time frame: 12 months per patient

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.